Aadi Bioscience Inc AADI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AADI is a good fit for your portfolio.
News
-
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
-
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
-
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
-
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
-
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?
-
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
-
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
Trading Information
- Previous Close Price
- $1.78
- Day Range
- $1.66–1.75
- 52-Week Range
- $1.55–8.60
- Bid/Ask
- $1.63 / $1.81
- Market Cap
- $41.25 Mil
- Volume/Avg
- 166,974 / 355,875
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 89
- Website
- https://www.aadibio.com
Comparables
Valuation
|
Metric
|
AADI
|
PRLD
|
CRBU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.39 | 0.94 | 0.90 |
Price/Sales | 1.86 | — | 8.05 |
Price/Cash Flow | — | — | — |
Price/Earnings
AADI
PRLD
CRBU
Financial Strength
|
Metric
|
AADI
|
PRLD
|
CRBU
|
|---|---|---|---|
Quick Ratio | 6.10 | 10.67 | 11.75 |
Current Ratio | 6.48 | 10.79 | 11.97 |
Interest Coverage | −301.71 | — | — |
Quick Ratio
AADI
PRLD
CRBU
Profitability
|
Metric
|
AADI
|
PRLD
|
CRBU
|
|---|---|---|---|
Return on Assets (Normalized) | −34.57% | −38.93% | −23.27% |
Return on Equity (Normalized) | −40.82% | −43.41% | −28.24% |
Return on Invested Capital (Normalized) | −45.00% | −42.59% | −26.03% |
Return on Assets
AADI
PRLD
CRBU
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ysxsnpywp | Fcxd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cwrvryl | Wzxdwn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zzltrymq | Qfyfby | $97.8 Bil | |
MRNA
| Moderna Inc | Bwmnlpps | Zdxyc | $38.8 Bil | |
ARGX
| argenx SE ADR | Jyylrmwm | Skgx | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Gfnqjkpz | Tkxt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dckbknvt | Lbkskq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rtnldsj | Fpxgzf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wcgssfhmhz | Nwdbhk | $12.5 Bil | |
INCY
| Incyte Corp | Tjkfsnt | Qhqvh | $11.5 Bil |